Living

UK's GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion

By Reuters Reuters
FILE PHOTO: Signage is pictured in the main lobby of GSK offices in London, Britain, February 20, 2025. REUTERS/Chris J. Ratcliffe/File Photo
FILE PHOTO: Signage is pictured in the main lobby of GSK offices in London, Britain, February 20, 2025. REUTERS/Chris J. Ratcliffe/File Photo Chris J Ratcliffe Reuters

British drugmaker GSK on Tuesday agreed to acquire U.S.-listed cancer drug developer Nuvalent for $10.6 billion.

(Reporting by DhanushVignesh Babu and Yadarisa Shabong in Bengaluru)

Copyright Reuters or USA Today Network via Reuters Connect

This story was originally published June 8, 2026 at 11:04 PM.

Get one year of unlimited digital access for $159.99
#ReadLocal

Only 44¢ per day

SUBSCRIBE NOW